Phase 3 Clinical Trials With Primary Completion Dates in June 2022

This is a list of Phase 3 trials with primary completion dates in June 2022 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
AKBA Akebia Therapeutics, Inc. 2022-06-01 Phase 3 NCT04707768 Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects
AORT Artivion, Inc. 2022-06-01 Phase 3 NCT04142658 PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban
ATNM Actinium Pharmaceuticals, Inc. 2022-06-01 Phase 3 NCT02665065 Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
ATRA Atara Biotherapeutics, Inc. 2022-06-01 Phase 3 NCT03394365 Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy
CLVS Clovis Oncology, Inc. 2022-06-01 Phase 3 NCT02975934 A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
CNCE Concert Pharmaceuticals, Inc. 2022-06-01 Phase 3 NCT04797650 A Phase 3 Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata (THRIVE-AA2)
EBS Emergent BioSolutions Inc. 2022-06-01 Phase 3 NCT05072080 A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317
EPZM Epizyme, Inc. 2022-06-01 Phase 3 NCT04224493 Study in Subjects With Relapsed/Refractory Follicular Lymphoma
EXEL Exelixis, Inc. 2022-06-01 Phase 3 NCT03937219 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
FAMDF Futura Medical plc 2022-06-01 Phase 3 NCT04984993 Clinical Investigation Using MED3000 Gel or Tadalafil Tablets in the Treatment of Erectile Dysfunction
FOLD Amicus Therapeutics, Inc. 2022-06-01 Phase 3 NCT04049760 Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease
NEPH Nephros, Inc. 2022-06-01 Phase 3 NCT04591015 Dulce Digital-COVID Aware (DD-CA) Discharge Texting Platform for US/Mexico Border Hispanics With Diabetes + COVID-19
NKTR Nektar Therapeutics 2022-06-01 Phase 3 NCT03729245 A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
NVAX Novavax, Inc. 2022-06-01 Phase 3 NCT05372588 Phase 3 Booster Study for the SARS-CoV-2 rS Vaccines
RLMD Relmada Therapeutics, Inc. 2022-06-01 Phase 3 NCT05081167 A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)
TVTX Travere Therapeutics, Inc. 2022-06-01 Phase 3 NCT03493685 Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
URGN UroGen Pharma Ltd. 2022-06-01 Phase 3 NCT05136898 Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC)